Global Liver Fibrosis Clinical Trials Review Market Growth, Trend & Forecast to 2015 Radiant Insights, Inc
Summary Radiant Insights's clinical trial report, "Liver Fibrosis Global Clinical Trials Review, H1, 2015" provides data on the Liver Fibrosis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Liver Fibrosis . It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Liver Fibrosis . This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Radiant Insights's team of industry experts. Read Complete Report with TOC @ http://www.radiantinsights.com/research/liver-fibrosis-global-clinical-trials-review-h1-2015 Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Reason to Buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Summary
Radiant Insights's clinical trial report, "Liver Fibrosis Global Clinical Trials Review, H1, 2015" provides data on the Liver Fibrosis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Liver Fibrosis . It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Liver Fibrosis . This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Radiant Insights's team of industry experts.
Read Complete Report with TOC @ http://www.radiantinsights.com/research/liver-fibrosis-global-clinical-trials-review-h1-2015
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)
Reason to Buy
- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>Global</strong> <strong>Liver</strong> <strong>Fibrosis</strong> <strong>Clinical</strong> <strong>Trials</strong> <strong>Review</strong> <strong>Market</strong> <strong>Growth</strong>,<br />
<strong>Trend</strong> & <strong>Forecast</strong> <strong>to</strong> <strong>2015</strong>: <strong>Radiant</strong> <strong>Insights</strong>, <strong>Inc</strong><br />
Summary<br />
<strong>Radiant</strong> <strong>Insights</strong>'s clinical trial report, "<strong>Liver</strong> <strong>Fibrosis</strong> <strong>Global</strong> <strong>Clinical</strong> <strong>Trials</strong> <strong>Review</strong>, H1, <strong>2015</strong>"<br />
provides data on the <strong>Liver</strong> <strong>Fibrosis</strong> clinical trial scenario. This report provides elemental information<br />
and data relating <strong>to</strong> the clinical trials on <strong>Liver</strong> <strong>Fibrosis</strong> . It includes an overview of the trial numbers<br />
and their recruitment status as per the site of trial conduction across the globe. The databook offers a<br />
preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors<br />
and also provides briefing pertaining <strong>to</strong> the number of trials for the key drugs for treating <strong>Liver</strong><br />
<strong>Fibrosis</strong> . This report is built using data and information sourced from proprietary databases, primary<br />
and secondary research and in-house analysis by <strong>Radiant</strong> <strong>Insights</strong>'s team of industry experts.<br />
Read Complete Report with TOC @ http://www.radiantinsights.com/research/liver-fibrosisglobal-clinical-trials-review-h1-<strong>2015</strong><br />
Scope<br />
- Data on the number of clinical trials conducted in North America, South and Central America,<br />
Europe, Middle-East and Africa and Asia-pacific and <strong>to</strong>p five national contributions in each<br />
- <strong>Clinical</strong> trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor<br />
type<br />
- Listings of discontinued trials (suspended, withdrawn and terminated)<br />
Reason <strong>to</strong> Buy<br />
- Understand the dynamics of a particular indication in a condensed manner<br />
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor<br />
type and many more<br />
- Obtain discontinued trial listing for trials across the globe<br />
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies<br />
Table of Contents<br />
Table of Contents 2<br />
List of Tables 4<br />
List of Figures 5<br />
Introduction 6
<strong>Liver</strong> <strong>Fibrosis</strong> 6<br />
Report Guidance 6<br />
<strong>Clinical</strong> <strong>Trials</strong> by Region 7<br />
<strong>Clinical</strong> <strong>Trials</strong> and Average Enrollment by Country 8<br />
Top Five Countries Contributing <strong>to</strong> <strong>Clinical</strong> <strong>Trials</strong> in Asia-Pacific 10<br />
Top Five Countries Contributing <strong>to</strong> <strong>Clinical</strong> <strong>Trials</strong> in Europe 11<br />
Top Countries Contributing <strong>to</strong> <strong>Clinical</strong> <strong>Trials</strong> in North America 12<br />
Top Five Countries Contributing <strong>to</strong> <strong>Clinical</strong> <strong>Trials</strong> in Middle East and Africa 13<br />
Top Countries Contributing <strong>to</strong> <strong>Clinical</strong> <strong>Trials</strong> in Central and South America 14<br />
<strong>Clinical</strong> <strong>Trials</strong> by G7 Countries: Proportion of <strong>Liver</strong> <strong>Fibrosis</strong> <strong>to</strong> Gastrointestinal <strong>Clinical</strong> <strong>Trials</strong> 15<br />
<strong>Clinical</strong> <strong>Trials</strong> by Phase in G7 Countries 16<br />
<strong>Clinical</strong> <strong>Trials</strong> in G7 Countries by Trial Status 17<br />
Read Complete Report with TOC @ http://www.radiantinsights.com/research/liver-fibrosisglobal-clinical-trials-review-h1-<strong>2015</strong><br />
<strong>Clinical</strong> <strong>Trials</strong> by E7 Countries: Proportion of <strong>Liver</strong> <strong>Fibrosis</strong> <strong>to</strong> Gastrointestinal <strong>Clinical</strong> <strong>Trials</strong> 18<br />
<strong>Clinical</strong> <strong>Trials</strong> by Phase in E7 Countries 19<br />
<strong>Clinical</strong> <strong>Trials</strong> in E7 Countries by Trial Status 20<br />
<strong>Clinical</strong> <strong>Trials</strong> by Phase 21<br />
In Progress <strong>Trials</strong> by Phase 22<br />
<strong>Clinical</strong> <strong>Trials</strong> by Trial Status 23<br />
<strong>Clinical</strong> <strong>Trials</strong> by End Point Status 24<br />
Unaccomplished <strong>Trials</strong> of <strong>Liver</strong> <strong>Fibrosis</strong> 25<br />
Subjects Recruited Over a Period of Time 27<br />
<strong>Clinical</strong> <strong>Trials</strong> by Sponsor Type 28<br />
Prominent Sponsors 29<br />
Top Companies Participating in <strong>Liver</strong> <strong>Fibrosis</strong> Therapeutics <strong>Clinical</strong> <strong>Trials</strong> 30<br />
Prominent Drugs 32<br />
Latest <strong>Clinical</strong> <strong>Trials</strong> News on <strong>Liver</strong> <strong>Fibrosis</strong> 33
Mar 12, <strong>2015</strong>: Galectin Therapeutics Engages PPD <strong>to</strong> Conduct GR-MD-02 Phase 2 Trial in NASH,<br />
Submits Special Pro<strong>to</strong>col Assessment <strong>to</strong> FDA 33<br />
<strong>Clinical</strong> Trial Profiles 34<br />
<strong>Clinical</strong> Trial Overview of Top Companies 34<br />
Merck & Co., <strong>Inc</strong>. 34<br />
<strong>Clinical</strong> Trial Overview of Merck & Co., <strong>Inc</strong>. 34<br />
F. Hoffmann-La Roche Ltd. 35<br />
<strong>Clinical</strong> Trial Overview of F. Hoffmann-La Roche Ltd. 35<br />
Pfizer <strong>Inc</strong>. 36<br />
<strong>Clinical</strong> Trial Overview of Pfizer <strong>Inc</strong>. 36<br />
Gilead Sciences, <strong>Inc</strong>. 37<br />
<strong>Clinical</strong> Trial Overview of Gilead Sciences, <strong>Inc</strong>. 37<br />
Read Complete Report with TOC @ http://www.radiantinsights.com/research/liver-fibrosisglobal-clinical-trials-review-h1-<strong>2015</strong><br />
Nit<strong>to</strong> Denko Corporation 38<br />
<strong>Clinical</strong> Trial Overview of Nit<strong>to</strong> Denko Corporation 38<br />
Galectin Therapeutics, <strong>Inc</strong>. 39<br />
<strong>Clinical</strong> Trial Overview of Galectin Therapeutics, <strong>Inc</strong>. 39<br />
C. H. Boehringer Sohn AG & Co. KG 40<br />
<strong>Clinical</strong> Trial Overview of C. H. Boehringer Sohn AG & Co. KG 40<br />
FibroGen, <strong>Inc</strong>. 41<br />
<strong>Clinical</strong> Trial Overview of FibroGen, <strong>Inc</strong>. 41<br />
Conatus Pharmaceuticals <strong>Inc</strong>. 42<br />
<strong>Clinical</strong> Trial Overview of Conatus Pharmaceuticals <strong>Inc</strong>. 42<br />
Astellas Pharma <strong>Inc</strong>. 43<br />
<strong>Clinical</strong> Trial Overview of Astellas Pharma <strong>Inc</strong>. 43<br />
<strong>Clinical</strong> Trial Overview of Top Institutes / Government 44<br />
Imperial College London 44<br />
<strong>Clinical</strong> Trial Overview of Imperial College London 44
302 Military Hospital of China 45<br />
<strong>Clinical</strong> Trial Overview of 302 Military Hospital of China 45<br />
Beijing Friendship Hospital 46<br />
<strong>Clinical</strong> Trial Overview of Beijing Friendship Hospital 46<br />
French National Agency for Research on AIDS and Viral Hepatitis 47<br />
<strong>Clinical</strong> Trial Overview of French National Agency for Research on AIDS and Viral Hepatitis 47<br />
McGill University Health Center 48<br />
<strong>Clinical</strong> Trial Overview of McGill University Health Center 48<br />
The National Institute of Diabetes and Digestive and Kidney Diseases 49<br />
<strong>Clinical</strong> Trial Overview of The National Institute of Diabetes and Digestive and Kidney Diseases 49<br />
Academic Medical Center 50<br />
Read Complete Report with TOC @ http://www.radiantinsights.com/research/liver-fibrosisglobal-clinical-trials-review-h1-<strong>2015</strong><br />
<strong>Clinical</strong> Trial Overview of Academic Medical Center 50<br />
Addenbrooke's Hospital 51<br />
<strong>Clinical</strong> Trial Overview of Addenbrooke's Hospital 51<br />
Azienda Ospedaliera Policlinico di Modena 52<br />
<strong>Clinical</strong> Trial Overview of Azienda Ospedaliera Policlinico di Modena 52<br />
Beijing 302 Hospital 53<br />
<strong>Clinical</strong> Trial Overview of Beijing 302 Hospital 53<br />
Five Key <strong>Clinical</strong> Profiles 54<br />
Appendix 73<br />
Abbreviations 73<br />
Definitions 73<br />
Research Methodology 74<br />
Secondary Research 74<br />
About <strong>Global</strong>Data 75<br />
Contact Us 75
Disclaimer 75<br />
Source 75<br />
List of Tables<br />
<strong>Liver</strong> <strong>Fibrosis</strong> Therapeutics, <strong>Global</strong>, <strong>Clinical</strong> <strong>Trials</strong> by Region, <strong>2015</strong>* 7<br />
<strong>Liver</strong> <strong>Fibrosis</strong> Therapeutics, <strong>Global</strong>, <strong>Clinical</strong> <strong>Trials</strong> and Average Enrollment by Top Countries, <strong>2015</strong>*<br />
8<br />
<strong>Liver</strong> <strong>Fibrosis</strong> Therapeutics, <strong>Global</strong>, <strong>Clinical</strong> <strong>Trials</strong> In Progress by Top Countries, <strong>2015</strong>* 9<br />
<strong>Liver</strong> <strong>Fibrosis</strong> Therapeutics <strong>Clinical</strong> <strong>Trials</strong>, Asia-Pacific, Top Five Countries, <strong>2015</strong>* 10<br />
<strong>Liver</strong> <strong>Fibrosis</strong> Therapeutics <strong>Clinical</strong> <strong>Trials</strong>, Europe, Top Five Countries, <strong>2015</strong>* 11<br />
<strong>Liver</strong> <strong>Fibrosis</strong> Therapeutics <strong>Clinical</strong> <strong>Trials</strong>, North America, Top Countries, <strong>2015</strong>* 12<br />
<strong>Liver</strong> <strong>Fibrosis</strong> Therapeutics <strong>Clinical</strong> <strong>Trials</strong>, Middle East and Africa, Top Five Countries, <strong>2015</strong>* 13<br />
<strong>Liver</strong> <strong>Fibrosis</strong> Therapeutics <strong>Clinical</strong> <strong>Trials</strong>, Central and South America, Top Countries, <strong>2015</strong>* 14<br />
Read Complete Report with TOC @ http://www.radiantinsights.com/research/liver-fibrosisglobal-clinical-trials-review-h1-<strong>2015</strong><br />
Proportion of <strong>Liver</strong> <strong>Fibrosis</strong> <strong>to</strong> Gastrointestinal <strong>Clinical</strong> <strong>Trials</strong>, G7 Countries (%), <strong>2015</strong>* 15<br />
<strong>Liver</strong> <strong>Fibrosis</strong> Therapeutics, G7 Countries, <strong>Clinical</strong> <strong>Trials</strong> by Phase, <strong>2015</strong>* 16<br />
<strong>Liver</strong> <strong>Fibrosis</strong> Therapeutics, G7 Countries, <strong>Clinical</strong> <strong>Trials</strong> by Trial Status, <strong>2015</strong>* 17<br />
Proportion of <strong>Liver</strong> <strong>Fibrosis</strong> <strong>to</strong> Gastrointestinal <strong>Clinical</strong> <strong>Trials</strong>, E7 Countries (%), <strong>2015</strong>* 18<br />
<strong>Liver</strong> <strong>Fibrosis</strong> Therapeutics, E7 Countries, <strong>Clinical</strong> <strong>Trials</strong> by Phase, <strong>2015</strong>* 19<br />
<strong>Liver</strong> <strong>Fibrosis</strong> Therapeutics, E7 Countries, <strong>Clinical</strong> <strong>Trials</strong> by Trial Status, <strong>2015</strong>* 20<br />
<strong>Liver</strong> <strong>Fibrosis</strong> Therapeutics, <strong>Global</strong>, <strong>Clinical</strong> <strong>Trials</strong> by Phase, <strong>2015</strong>* 21<br />
<strong>Liver</strong> <strong>Fibrosis</strong> Therapeutics, <strong>Global</strong>, <strong>Clinical</strong> <strong>Trials</strong> In Progress by Phase <strong>2015</strong>* 22<br />
<strong>Liver</strong> <strong>Fibrosis</strong> Therapeutics, <strong>Global</strong>, <strong>Clinical</strong> <strong>Trials</strong> by Trial Status, <strong>2015</strong>* 23<br />
<strong>Liver</strong> <strong>Fibrosis</strong> Therapeutics <strong>Clinical</strong> <strong>Trials</strong>, <strong>Global</strong>, by End Point Status, <strong>2015</strong>* 24<br />
<strong>Liver</strong> <strong>Fibrosis</strong> Therapeutics, <strong>Global</strong>, Withdrawn <strong>Clinical</strong> <strong>Trials</strong>, <strong>2015</strong>* 25<br />
<strong>Liver</strong> <strong>Fibrosis</strong> Therapeutics, <strong>Global</strong>, Terminated <strong>Clinical</strong> <strong>Trials</strong>, <strong>2015</strong>* 26<br />
<strong>Liver</strong> <strong>Fibrosis</strong> Therapeutics <strong>Clinical</strong> <strong>Trials</strong>, <strong>Global</strong>, Average Enrollment Target <strong>Trend</strong>s, 2010-2014 27<br />
<strong>Liver</strong> <strong>Fibrosis</strong> Therapeutics <strong>Market</strong>, <strong>Global</strong>, <strong>Clinical</strong> <strong>Trials</strong> by Sponsor Type, <strong>2015</strong>* 28
<strong>Liver</strong> <strong>Fibrosis</strong> Therapeutics <strong>Clinical</strong> <strong>Trials</strong>, <strong>Global</strong>, Key Sponsors, <strong>2015</strong>* 29<br />
<strong>Liver</strong> <strong>Fibrosis</strong> Therapeutics <strong>Clinical</strong> <strong>Trials</strong>, <strong>Global</strong>, Top Companies by Phase, <strong>2015</strong>* 31<br />
<strong>Liver</strong> <strong>Fibrosis</strong> Therapeutics <strong>Clinical</strong> <strong>Trials</strong>, <strong>Global</strong>, Ongoing <strong>Clinical</strong> <strong>Trials</strong> by Prominent Drugs,<br />
<strong>2015</strong>* 32<br />
<strong>Liver</strong> <strong>Fibrosis</strong> Therapeutics <strong>Clinical</strong> <strong>Trials</strong> <strong>Market</strong>, <strong>Global</strong>, <strong>Clinical</strong> <strong>Trials</strong> by Merck & Co., <strong>Inc</strong>.,<br />
<strong>2015</strong>* 34<br />
<strong>Liver</strong> <strong>Fibrosis</strong> Therapeutics <strong>Clinical</strong> <strong>Trials</strong> <strong>Market</strong>, <strong>Global</strong>, <strong>Clinical</strong> <strong>Trials</strong> by F. Hoffmann-La Roche<br />
Ltd., <strong>2015</strong>* 35<br />
<strong>Liver</strong> <strong>Fibrosis</strong> Therapeutics <strong>Clinical</strong> <strong>Trials</strong> <strong>Market</strong>, <strong>Global</strong>, <strong>Clinical</strong> <strong>Trials</strong> by Pfizer <strong>Inc</strong>., <strong>2015</strong>* 36<br />
<strong>Liver</strong> <strong>Fibrosis</strong> Therapeutics <strong>Clinical</strong> <strong>Trials</strong> <strong>Market</strong>, <strong>Global</strong>, <strong>Clinical</strong> <strong>Trials</strong> by Gilead Sciences, <strong>Inc</strong>.,<br />
<strong>2015</strong>* 37<br />
<strong>Liver</strong> <strong>Fibrosis</strong> Therapeutics <strong>Clinical</strong> <strong>Trials</strong> <strong>Market</strong>, <strong>Global</strong>, <strong>Clinical</strong> <strong>Trials</strong> by Nit<strong>to</strong> Denko<br />
Corporation, <strong>2015</strong>* 38<br />
Read Complete Report with TOC @ http://www.radiantinsights.com/research/liver-fibrosisglobal-clinical-trials-review-h1-<strong>2015</strong><br />
<strong>Liver</strong> <strong>Fibrosis</strong> Therapeutics <strong>Clinical</strong> <strong>Trials</strong> <strong>Market</strong>, <strong>Global</strong>, <strong>Clinical</strong> <strong>Trials</strong> by Galectin Therapeutics,<br />
<strong>Inc</strong>., <strong>2015</strong>* 39<br />
<strong>Liver</strong> <strong>Fibrosis</strong> Therapeutics <strong>Clinical</strong> <strong>Trials</strong> <strong>Market</strong>, <strong>Global</strong>, <strong>Clinical</strong> <strong>Trials</strong> by C. H. Boehringer Sohn<br />
AG & Co. KG, <strong>2015</strong>* 40<br />
<strong>Liver</strong> <strong>Fibrosis</strong> Therapeutics <strong>Clinical</strong> <strong>Trials</strong> <strong>Market</strong>, <strong>Global</strong>, <strong>Clinical</strong> <strong>Trials</strong> by FibroGen, <strong>Inc</strong>., <strong>2015</strong>*<br />
41<br />
<strong>Liver</strong> <strong>Fibrosis</strong> Therapeutics <strong>Clinical</strong> <strong>Trials</strong> <strong>Market</strong>, <strong>Global</strong>, <strong>Clinical</strong> <strong>Trials</strong> by Conatus<br />
Pharmaceuticals <strong>Inc</strong>., <strong>2015</strong>* 42<br />
<strong>Liver</strong> <strong>Fibrosis</strong> Therapeutics <strong>Clinical</strong> <strong>Trials</strong> <strong>Market</strong>, <strong>Global</strong>, <strong>Clinical</strong> <strong>Trials</strong> by Astellas Pharma <strong>Inc</strong>.,<br />
<strong>2015</strong>* 43<br />
<strong>Liver</strong> <strong>Fibrosis</strong> Therapeutics <strong>Clinical</strong> <strong>Trials</strong> <strong>Market</strong>, <strong>Global</strong>, <strong>Clinical</strong> <strong>Trials</strong> by Imperial College<br />
London, <strong>2015</strong>* 44<br />
<strong>Liver</strong> <strong>Fibrosis</strong> Therapeutics <strong>Clinical</strong> <strong>Trials</strong> <strong>Market</strong>, <strong>Global</strong>, <strong>Clinical</strong> <strong>Trials</strong> by 302 Military Hospital of<br />
China, <strong>2015</strong>* 45<br />
<strong>Liver</strong> <strong>Fibrosis</strong> Therapeutics <strong>Clinical</strong> <strong>Trials</strong> <strong>Market</strong>, <strong>Global</strong>, <strong>Clinical</strong> <strong>Trials</strong> by Beijing Friendship<br />
Hospital, <strong>2015</strong>* 46<br />
<strong>Liver</strong> <strong>Fibrosis</strong> Therapeutics <strong>Clinical</strong> <strong>Trials</strong> <strong>Market</strong>, <strong>Global</strong>, <strong>Clinical</strong> <strong>Trials</strong> by French National Agency<br />
for Research on AIDS and Viral Hepatitis, <strong>2015</strong>* 47
<strong>Liver</strong> <strong>Fibrosis</strong> Therapeutics <strong>Clinical</strong> <strong>Trials</strong> <strong>Market</strong>, <strong>Global</strong>, <strong>Clinical</strong> <strong>Trials</strong> by McGill University<br />
Health Center, <strong>2015</strong>* 48<br />
<strong>Liver</strong> <strong>Fibrosis</strong> Therapeutics <strong>Clinical</strong> <strong>Trials</strong> <strong>Market</strong>, <strong>Global</strong>, <strong>Clinical</strong> <strong>Trials</strong> by The National Institute of<br />
Diabetes and Digestive and Kidney Diseases, <strong>2015</strong>* 49<br />
<strong>Liver</strong> <strong>Fibrosis</strong> Therapeutics <strong>Clinical</strong> <strong>Trials</strong> <strong>Market</strong>, <strong>Global</strong>, <strong>Clinical</strong> <strong>Trials</strong> by Academic Medical<br />
Center, <strong>2015</strong>* 50<br />
<strong>Liver</strong> <strong>Fibrosis</strong> Therapeutics <strong>Clinical</strong> <strong>Trials</strong> <strong>Market</strong>, <strong>Global</strong>, <strong>Clinical</strong> <strong>Trials</strong> by Addenbrooke's<br />
Hospital, <strong>2015</strong>* 51<br />
<strong>Liver</strong> <strong>Fibrosis</strong> Therapeutics <strong>Clinical</strong> <strong>Trials</strong> <strong>Market</strong>, <strong>Global</strong>, <strong>Clinical</strong> <strong>Trials</strong> by Azienda Ospedaliera<br />
Policlinico di Modena, <strong>2015</strong>* 52<br />
<strong>Liver</strong> <strong>Fibrosis</strong> Therapeutics <strong>Clinical</strong> <strong>Trials</strong> <strong>Market</strong>, <strong>Global</strong>, <strong>Clinical</strong> <strong>Trials</strong> by Beijing 302 Hospital,<br />
<strong>2015</strong>* 53<br />
Read Complete Report with TOC @ http://www.radiantinsights.com/research/liver-fibrosisglobal-clinical-trials-review-h1-<strong>2015</strong><br />
List of Figures<br />
<strong>Liver</strong> <strong>Fibrosis</strong> Therapeutics, <strong>Global</strong>, <strong>Clinical</strong> <strong>Trials</strong> by Region (%), <strong>2015</strong>* 7<br />
<strong>Liver</strong> <strong>Fibrosis</strong> Therapeutics, <strong>Global</strong>, <strong>Clinical</strong> <strong>Trials</strong> and Average Enrollment by Top Countries, <strong>2015</strong>*<br />
8<br />
<strong>Liver</strong> <strong>Fibrosis</strong> Therapeutics, <strong>Global</strong>, <strong>Clinical</strong> <strong>Trials</strong> In Progress by Top Countries, <strong>2015</strong>* 9<br />
<strong>Liver</strong> <strong>Fibrosis</strong> Therapeutics <strong>Clinical</strong> <strong>Trials</strong>, Asia-Pacific, Top Five Countries (%), <strong>2015</strong>* 10<br />
<strong>Liver</strong> <strong>Fibrosis</strong> Therapeutics <strong>Clinical</strong> <strong>Trials</strong>, Europe, Top Five Countries (%), <strong>2015</strong>* 11<br />
<strong>Liver</strong> <strong>Fibrosis</strong> Therapeutics <strong>Clinical</strong> <strong>Trials</strong>, North America, Top Countries (%), <strong>2015</strong>* 12<br />
<strong>Liver</strong> <strong>Fibrosis</strong> Therapeutics <strong>Clinical</strong> <strong>Trials</strong>, Middle East and Africa, Top Five Countries (%), <strong>2015</strong>*<br />
13<br />
<strong>Liver</strong> <strong>Fibrosis</strong> Therapeutics <strong>Clinical</strong> <strong>Trials</strong>, Central and South America, Top Countries (%), <strong>2015</strong>* 14<br />
Proportion of <strong>Liver</strong> <strong>Fibrosis</strong> <strong>to</strong> Gastrointestinal <strong>Clinical</strong> <strong>Trials</strong>, G7 Countries (%), <strong>2015</strong>* 15<br />
<strong>Liver</strong> <strong>Fibrosis</strong> Therapeutics, G7 Countries, <strong>Clinical</strong> <strong>Trials</strong> by Phase, <strong>2015</strong>* 16<br />
<strong>Liver</strong> <strong>Fibrosis</strong> Therapeutics, G7 Countries, <strong>Clinical</strong> <strong>Trials</strong> by Trial Status, <strong>2015</strong>* 17<br />
Proportion of <strong>Liver</strong> <strong>Fibrosis</strong> <strong>to</strong> Gastrointestinal <strong>Clinical</strong> <strong>Trials</strong>, E7 Countries (%), <strong>2015</strong>* 18<br />
<strong>Liver</strong> <strong>Fibrosis</strong> Therapeutics, E7 Countries, <strong>Clinical</strong> <strong>Trials</strong> by Phase, <strong>2015</strong>* 19<br />
<strong>Liver</strong> <strong>Fibrosis</strong> Therapeutics, E7 Countries, <strong>Clinical</strong> <strong>Trials</strong> by Trial Status, <strong>2015</strong>* 20
<strong>Liver</strong> <strong>Fibrosis</strong> Therapeutics, <strong>Global</strong>, <strong>Clinical</strong> <strong>Trials</strong> by Phase (%), <strong>2015</strong>* 21<br />
<strong>Liver</strong> <strong>Fibrosis</strong> Therapeutics, <strong>Global</strong>, <strong>Clinical</strong> <strong>Trials</strong> In Progress by Phase, <strong>2015</strong>* 22<br />
<strong>Liver</strong> <strong>Fibrosis</strong> Therapeutics, <strong>Global</strong>, <strong>Clinical</strong> <strong>Trials</strong> by Trial Status, <strong>2015</strong>* 23<br />
<strong>Liver</strong> <strong>Fibrosis</strong> Therapeutics <strong>Clinical</strong> <strong>Trials</strong>, <strong>Global</strong>, by End Point Status, <strong>2015</strong>* 24<br />
<strong>Liver</strong> <strong>Fibrosis</strong> Therapeutics <strong>Clinical</strong> <strong>Trials</strong>, <strong>Global</strong>, Average Enrollment Target <strong>Trend</strong>s, 2010-2014 27<br />
<strong>Liver</strong> <strong>Fibrosis</strong> Therapeutics <strong>Market</strong>, <strong>Global</strong>, <strong>Clinical</strong> <strong>Trials</strong> by Sponsor Type (%), <strong>2015</strong>* 28<br />
<strong>Liver</strong> <strong>Fibrosis</strong> Therapeutics <strong>Clinical</strong> <strong>Trials</strong>, <strong>Global</strong>, Key Sponsors, <strong>2015</strong>* 29<br />
<strong>Liver</strong> <strong>Fibrosis</strong> Therapeutics <strong>Clinical</strong> <strong>Trials</strong>, <strong>Global</strong>, Top Companies by Phase, <strong>2015</strong>* 30<br />
<strong>Liver</strong> <strong>Fibrosis</strong> Therapeutics <strong>Clinical</strong> <strong>Trials</strong>, <strong>Global</strong>, Ongoing <strong>Clinical</strong> <strong>Trials</strong> by Prominent Drugs,<br />
<strong>2015</strong>* 32<br />
Read Complete Report with TOC @ http://www.radiantinsights.com/research/liver-fibrosisglobal-clinical-trials-review-h1-<strong>2015</strong><br />
About <strong>Radiant</strong> <strong>Insights</strong><br />
<strong>Radiant</strong> <strong>Insights</strong> is a platform for companies looking <strong>to</strong> meet their market research and business<br />
intelligence requirements. We assist and facilitate organizations and individuals procure market<br />
research reports, helping them in the decision making process. We have a comprehensive collection of<br />
reports, covering over 40 key industries and a host of micro markets. In addition <strong>to</strong> over extensive<br />
database of reports, our experienced research coordina<strong>to</strong>rs also offer a host of ancillary services such<br />
as, research partnerships/ tie-ups and cus<strong>to</strong>mized research solutions.<br />
For More Information, Visit <strong>Radiant</strong> <strong>Insights</strong><br />
Contact:<br />
Michelle Thoras<br />
Corporate Sales Specialist, USA<br />
<strong>Radiant</strong> <strong>Insights</strong>, <strong>Inc</strong><br />
Phone: 1-415-349-0054<br />
Toll Free: 1-888-202-9519<br />
Email: sales@radiantinsights.com<br />
Blog URL: http://www.radiantinsightsinc.blogspot.com
Change language